The epidemiology of nonalcoholic fatty liver disease: a global perspective.

By Mariana Lazo, J. Clark. Seminars in liver disease (Print), 2008

782 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/beace1cfb2ce923e386c41908b56846ab08f8bcb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Y. Kawano
2. D. Cohen
3. J. Clark
4. S. Caldwell
5. P. Ferré
6. Y. Sumida
7. F. Foufelle
8. G. Baffy

In Hepatology

1. Y. Kawano
2. D. Cohen
3. J. Clark
4. Y. Sumida
5. E. Brunt

In Pathology and Forensic Medicine

1. Y. Kawano
2. D. Cohen
3. J. Clark
4. E. Brunt

Citations in the corpus

• Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis (2011, methodology): “We included all studies that presented the following: (1) estimates of diagnostic accuracy (such as sensitivity or specificity), cross-tabulations, or correlations of B-mode ultrasonography to identify fatty liver against histology as the gold standard; (2) estimates of intra- or interrater reliabil”
• INCREASED FRUCTOSE CONSUMPTION IS ASSOCIATED WITH FIBROSIS SEVERITY IN PATIENTS WITH NAFLD (2010, background): “The healthcare burden and associated economic implication of the epidemic of obesity, diabetes, and the hepatic complications of the metabolic syndrome are tremendous.(3) Unfortunately, no therapy for nonalcoholic fatty liver disease (NAFLD) currently exists.”
• The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome (2010, background): “Every country that has adopted the fructose-rich, fiber-poor, and micronutrient-poor Western diet has suffered the same fate”
• Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease (2010, background): “Because fatty liver disease is often associated with obesity (23, 24, 25, 26), we hypothesized that the increased levels seen with rising BMI might reflect lipid accumulation in the liver.”
• Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c (2010, background): “Non-alcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver disease and is strongly associated with obesity, type 2 diabetes and insulin resistance [1,2].”
• Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. (2012, background): “NAFLD has become the most common liver disorder in the United States and other industrialized countries, affecting up to 30% of the general adult population and 90% of those with morbid obesity (body mass index greater than or equal to 40 kg/m(2)) [23,24].”
• Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. (2016, background): “7 Background Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic liver injury in many countries [1-2].”
• Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. (2013, background): “Large, population-based estimates of the prevalence of NAFLD as detected by ultrasonography are available for other Western and non-Western countries and show that its prevalence parallels that of obesity (11).”
• Mechanisms of Hepatic Triglyceride Accumulation in Nonalcoholic Fatty Liver Disease (2013, positive): “Estimates of the prevalence of NAFLD range widely from 11 to 46 % [4, 5].”